RecruitingEarly Phase 1NCT06419348

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET

Sponsor

First Affiliated Hospital of Chongqing Medical University

Enrollment

30 participants

Start Date

May 20, 2024

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Stage PSMA SPECT

Summary

99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new imaging agent called 99mTc-QULIC-5-P1 for detecting prostate cancer. The agent is injected and then a special scanner (SPECT) takes pictures to find where cancer cells are in the body — targeting a protein called PSMA that is commonly found on prostate cancer cells. **You may be eligible if...** - You are 18 or older - You have suspected, newly diagnosed, or previously treated prostate cancer - Your cancer tests positive for PSMA (a protein on cancer cells), confirmed by MRI, CT, or biopsy - You can give written consent **You may NOT be eligible if...** - Your prostate cancer tests PSMA-negative - You are pregnant - You are unable or unwilling to give consent - You have a known allergy to the imaging agent - You have a serious medical condition that could interfere with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.